Since My company is wrapping things up now until the middle of January, I will have a lot more time to review and post the clinical data.
The markets should be seeing a lot of action this week, so I will be on top of it!
Happy Holidays.
skip to main |
skip to sidebar
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
A Scientific Interpretation of Stock and Clinical Trial Data that's easy to understand
Check out Whatisthatdrug.com--new posts daily on drugs advertised in current media
Focal Adhesions: How cells crawl along
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
About Me
- Science Food Logic
- I have wet bench research experience in pharmacology, biochemistry and cell biology. Further, I have clinical research experience in ophthalmology, pathology and immunology. I am employed full time as a research scientist in the pharmaceutical industry. In my off time, I enjoy creating fine dining dishes as well as 20 minute meals that taste like fine dining. I like to teach both professionally and in the kitchen.
Blog Archive
-
▼
2006
(300)
-
▼
December
(33)
- Introgen Therapeutics phase III drug Advexin in fi...
- InterMune expected to move in Friday's trading:
- Nasdaq to close Tuesday for President Ford's funeral
- Threshold Pharma Stocks Up on Glufofamide trial data
- Cashing in at the end of the year: Cambrex CEO Se...
- Targacept shares jump on continued development of ...
- Adventrx to Begin Trials on Cancer Drug
- InterMune soars on positive drug news
- SciClone Pharmaceuticals, Inc. (SCLN) And Sigma-Ta...
- Thursday's Pharma Advancers:
- Nice Article on Biotechnology Stocks
- Genta cuts more than a third of its workforce
- Altus signs development deal with Genentech
- GenVec Surges on Trial Results
- ZLB to pay $120M for MedImmune drug
- Somaxon Pharmaceuticals, Inc.'s SILENOR Demonstrat...
- Posting
- Biopure Pressured by FDA Panel Vote
- Alexza completes trial--Stock Skyrockets
- Yesterday's Huge Mover: Progen Industries
- Charles River Laboratories Shares Jump on 2006, 20...
- Breaking News: Merck wins latest lawsuit
- Roche (RHHBY) Release: Xeloda(R) Combination Meets...
- BioCryst reports encouraging test results on anti-...
- FDA Approves Millennium Pharmaceuticals, Inc. VEL...
- Genta Shares Fall As Early Results Show Drug Did N...
- Sangamo Plans 4 Ongoing Trials in 2007
- Why did a promising heart drug fail?
- Oragenics Seeks Patent for Unique Gene Targets for...
- Micromet Surges on Milestone
- Pfizer ends cholesterol-drug development: Halts Cl...
- eGene Announces Initial Product Test Milestone of ...
- The Scripps Research Institute Enters Major Five-Y...
-
▼
December
(33)
1 comment:
yes but I mainly post in clinical trial data that influence a big stock move for a company or data that should be taken notice of that may only appear in scientific journals not available to the public.
Post a Comment